Tilray Brands, Inc. (NASDAQ:TLRY) Receives $15.00 Consensus Target Price from Brokerages

by · The Markets Daily

Shares of Tilray Brands, Inc. (NASDAQ:TLRY – Get Free Report) have received a consensus rating of “Reduce” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $13.3333.

TLRY has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday. Zacks Research downgraded shares of Tilray Brands from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Atb Cap Markets raised Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 10th. Wall Street Zen raised Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Roth Mkm cut their target price on Tilray Brands from $20.00 to $10.00 and set a “neutral” rating for the company in a research report on Tuesday, January 20th.

Get Our Latest Research Report on Tilray Brands

Hedge Funds Weigh In On Tilray Brands

Several hedge funds have recently modified their holdings of TLRY. Tidal Investments LLC boosted its position in shares of Tilray Brands by 15.0% during the second quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock worth $12,006,000 after acquiring an additional 3,776,410 shares during the last quarter. Millennium Management LLC lifted its stake in Tilray Brands by 281.0% in the 3rd quarter. Millennium Management LLC now owns 4,942,319 shares of the company’s stock worth $8,550,000 after purchasing an additional 3,645,060 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Tilray Brands in the 3rd quarter worth $5,813,000. Ausdal Financial Partners Inc. bought a new position in shares of Tilray Brands during the 2nd quarter valued at about $939,000. Finally, Swiss National Bank grew its position in shares of Tilray Brands by 4.4% during the third quarter. Swiss National Bank now owns 2,013,038 shares of the company’s stock valued at $3,483,000 after purchasing an additional 84,900 shares in the last quarter. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Tilray Brands Price Performance

NASDAQ TLRY opened at $9.05 on Tuesday. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -0.41 and a beta of 1.77. Tilray Brands has a 1-year low of $3.51 and a 1-year high of $23.20. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72. The business’s fifty day moving average price is $9.49 and its 200-day moving average price is $10.90.

Tilray Brands (NASDAQ:TLRY – Get Free Report) last announced its earnings results on Thursday, January 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.27). Tilray Brands had a negative net margin of 251.69% and a negative return on equity of 6.35%. The business had revenue of $217.51 million for the quarter, compared to the consensus estimate of $211.15 million. During the same quarter last year, the firm posted ($0.03) earnings per share. On average, equities analysts predict that Tilray Brands will post -0.2 earnings per share for the current year.

Tilray Brands Company Profile

(Get Free Report)

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.

Featured Stories